GlassScriptPhysician profile
Chris Raju
NPI 1992119812
$1,195.30
in general payments reported to CMS, 2019-2025
14 companies · $547 in 2025
The $547 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $37.07 · 2022: $166 · 2023: $55.26 · 2024: $265 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.48 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $340.71 | 2022-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $252.23 | 2025 | Veozah |
| Abbvie INC. | $131.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.49 | 2024 | Airsupra |
| Mayne Pharma Commercial LLC | $75.20 | 2025 | |
| Allergan, INC. | $52.97 | 2019 | |
| Organon LLC | $46.76 | 2022-2023 | Nexplanon |
| Millicent US INC | $38.01 | 2025 | Femlyv |
| Merck Sharp & Dohme LLC | $30.42 | 2019 | |
| Vertical Pharmaceuticals, LLC | $23.94 | 2019 | |
| Sumitomo Pharma America, INC. | $23.87 | 2025 | Myfembree |
| Exeltis, USA INC. | $23.33 | 2025 | Slynd |
| Avion Pharmaceuticals | $16.68 | 2022 | |
| Myovant Sciences INC. | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Raju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.